Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide

Author： Polyzos A.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.19, Iss.5, 2000-05, pp. : 349-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epirubicin plus vinorelbine useful in advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1453, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide

By Liubao Peng  

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 873-886

Adis International

Access to resources Recommend Favorite

Liposomal doxorubicin vs epirubicin in breast cancer

By  

Inpharma, Vol. 1, Iss. 1462, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

The GVAX cancer vaccine plus ipilimumab is active in the treatment of patients with advanced prostate cancer

By  

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors

By Medioni Jacques   Huchon Cyrille   >  

Drugs in R&D, Vol. 11, Iss. 2, 2011-06 ,pp. : 147-157

Adis International

Access to resources Recommend Favorite